Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

0.9586
+0.05576.17%
Post-market: 0.9500-0.0086-0.90%19:59 EDT
Volume:935.53K
Turnover:865.38K
Market Cap:4.25M
PE:-0.03
High:0.9789
Open:0.9100
Low:0.8720
Close:0.9029
Loading ...

Company Profile

Company Name:
Allarity Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
6
Office Location:
24 School Street,2nd Floor,Boston,Massachusetts,United States
Zip Code:
02108
Fax:
- -
Introduction:
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Duncan Moore
Chairman of the Board
James G. Cullem
Director, Interim Chief Executive Officer, Chief Business Officer, Senior Vice President, Corporate Development
David Roth
Independent Director
Gail Maderis
Independent Director
Gerald W. McLaughlin
Independent Director
Soren G. Jensen
Independent Director
Thomas H. Jensen
Director, Senior Vice President, Investor Relations

Shareholders

Name
Position
James G. Cullem
Director, Interim Chief Executive Officer, Chief Business Officer, Senior Vice President, Corporate Development
Joan Brown
Interim Chief Financial Officer
Thomas H. Jensen
Director, Senior Vice President, Investor Relations
Marie Foegh
Chief Medical Officer
Steen Knudsen
Chief Scientific Officer